A commercially purchased dynorphin preparation raised calcium levels in pituitary cells — but the effect was from LHRH contamination, not dynorphin itself.
LHRH contaminationIn a commercial synthetic dynorphin preparation — produced entirely misleading results
What the researchers found
A commercially purchased synthetic dynorphin A-(1-13) raised cytosolic calcium in rat pituitary cells. However, this effect was NOT caused by dynorphin itself.
When the same preparation was purified by HPLC, the calcium-raising effect disappeared. HPLC combined with LHRH radioimmunoassay revealed contamination with a LHRH-like compound (luteinizing hormone-releasing hormone).
The LHRH antagonist blocked the calcium effect, confirming the contamination. Pure dynorphin A-(1-13), dynorphin A-(2-13), leu-enkephalin, beta-endorphin, morphine, and U50,488H all had zero effect on pituitary calcium.
LHRH itself raised calcium by about 50 nM, which was blocked by the LHRH antagonist.
Why it matters
This is a critical warning about peptide purity. A commercially available research-grade peptide was contaminated enough to produce completely false results. Any study using unpurified commercial peptides could be reporting artifact effects. This finding has implications for both research integrity and for consumers of research peptides.
How the study worked
Rat anterior pituitary cells were loaded with fura-2 (a fluorescent calcium indicator). Calcium changes were measured in response to opioid peptides. HPLC purification separated dynorphin from contaminants. LHRH radioimmunoassay and receptor binding studies identified the contaminant.
What this study cannot tell us
Only one commercial preparation was tested. The specific contaminant was not fully identified (described as LHRH-like). The study focused on calcium effects; other contamination effects were not tested.
How to read the evidence
Preliminary but critically important quality control study with rigorous methodology.
When this study was published
Published in 1988 — an enduring cautionary tale for peptide quality control.
The bigger picture
This cautionary study shows that commercial peptide preparations can contain biologically active contaminants that produce misleading results. It underscores the need for rigorous quality control in peptide research and therapeutic use.
Questions still open
- How common is peptide contamination in commercial preparations?
- Should all commercial peptides be HPLC-verified before use?
Common questions
How was the contamination detected?
Does this affect therapeutic peptides?
Read the original research
Opioids and cytosolic calcium in rat anterior pituitary: dynorphin preparation showed LHRH-like action due to contamination.
Experientia, 44(11-12), 1003-5
Citation
Knepel, W; Schöfl, C; Wesemeyer, G; Götz, D M. (1988). Opioids and cytosolic calcium in rat anterior pituitary: dynorphin preparation showed LHRH-like action due to contamination.. Experientia, 44(11-12), 1003-5.